Fauna Bio

About

Fauna Bio is an AI-driven biotechnology company based in Emeryville, California. The company focuses on developing novel drug targets for human diseases by leveraging insights from the genetics of extreme mammals, such as hibernators. Fauna Bio utilizes its proprietary AI platform, Convergence, to analyze genetic data and identify conserved genetic pathways that can be targeted for drug development. The primary service offered by Fauna Bio is preclinical drug discovery, where it identifies and validates novel drug targets through cellular and in-vivo models. The company is actively involved in research initiatives, including programs that study the effects of microgravity on health and the protective mechanisms of hibernation. Notably, Fauna Bio has partnered with Eli Lilly to collaborate on drug target identification for obesity, with a multi-year agreement valued at up to $494 million. The team at Fauna Bio consists of experts in molecular biology, AI, and genomics, and the company is expanding its operations to support its drug discovery efforts.